Hims & Hers Health (NYSE:HIMS) Stock Price Up 4.5% – Still a Buy?

Hims & Hers Health, Inc. (NYSE:HIMS) shares rose 4.5% during mid-day trading on Monday . The company traded as high as $38.63 and last traded at $38.97. Approximately 5,949,811 shares changed hands during trading, a decline of 41% from the average daily volume of 10,106,234 shares. The stock had previously closed at $37.28.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent analyst reports. Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. Piper Sandler boosted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Trading Up 0.6 %

The stock’s fifty day moving average is $29.58 and its two-hundred day moving average is $22.86. The company has a market capitalization of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the previous year, the company earned ($0.04) earnings per share. The company’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $38.92, for a total value of $450,732.52. Following the completion of the sale, the chief financial officer now owns 112,933 shares of the company’s stock, valued at $4,395,352.36. This trade represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Anja Manuel bought 4,000 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $107,760. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 1,167,913 shares of company stock valued at $34,303,787 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares in the last quarter. US Bancorp DE raised its position in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after acquiring an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $48,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.